

DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.
Start date | Oct 1, 2018 |
End date | Nov 30, 2024 |
Funding Agency | Bavarian State Ministry of Health and Care |
Partners | Deutschen Herzzentrum München (DHM) BioM Biotech Cluster Development GmbH Projektträger Bayern, Bayern Innovativ GmbH Deutsche Herzstiftung Max-Planck-Institut für Biochemie Helmholtz Zentrum München Klinikum rechts der Isar der TU München LMU München TU München |
Total Budget | tba |